Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Quest Diagnostics Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.75 (market cap $39.89B), while Quest Diagnostics Inc trades at $209.42 (market cap $22.96B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.66% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DGX | |
|---|---|---|
Market Cap | $39.89B | $22.96B |
Sector | Health | Health |
52-Week High | $491.22 | $216.02 |
52-Week Low | $278.09 | $166.42 |
Enterprise Value | $38.15B | $28.98B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Quest Diagnostics (DGX) trades at $207.44, down 0.29% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported $11.04B revenue in 2025 with a 9.08% net margin, supported by strong cash flow from operations of $1.89B. Recent news highlights expansion of oncology testing services, including New York State approval for Haystack MRD, enhancing its diagnostic portfolio.
DGX offers steady growth with a consensus price target of $226, implying 9% upside. Risks include rising debt levels and healthcare policy uncertainties, but analyst sentiment leans positive with 38% buy ratings. The stock's valuation at a P/E of 22.92 appears reasonable given its profitability and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
